Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Neuroendocrine Tumors 2Neuroectodermal Tumors, Primitive 1Neoplasms 1Glioblastoma 1Brain Neoplasms 1

Interventions

Everolimus 2trifluridine tipiracil drug combination 1surufatinib 1pegfilgrastim 1pasireotide 1gallium Ga 68 dotatate 1fosbretabulin 1entinostat 1dactolisib 1belzutifan 1Temozolomide 1TH 302 1Surveys and Questionnaires 1Sunitinib 1Photochemotherapy 1Nivolumab 1Filgrastim 1Fentanyl 1Dihematoporphyrin Ether 190Y-octreotide, DOTA-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neuroectodermal Tumors, Primitive × dactolisib × Endocrine × Clear all
NCT01628913 2016-04-07

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Novartis

Phase 2 Terminated
62 enrolled 7 charts
EndocrineNET

Neuroectodermal Tumors, Primitive, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡